Status:
COMPLETED
Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.
Lead Sponsor:
Fundacion Clinic per a la Recerca Biomédica
Conditions:
HIV
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The main objective of this study is to compare the tolerability and adherence to a new drug regimen of post-exposure prophylaxis (PEP) for HIV,
Eligibility Criteria
Inclusion
- Age greater than 18 years
- Have been exposed to HIV, non-occupational and meets the requirements of current recommendations to start with three antiretroviral drugs PEP
- that adequately informed consent in writing to participate in the study and undergo testing and exploration that entails
Exclusion
- pregnant women, lactating, or those intend become pregnant during the study period.
- subjects who are known or suspected case presents the source resistors to one of the drugs of the pattern of study
- contraindicated treatment with the study drugs, or products under investigation
Key Trial Info
Start Date :
June 6 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT02198443
Start Date
June 6 2015
Last Update
February 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital clínico y provincial de Barcelona
Barcelona, Barcelona, Spain, 08036